| EndoTAG®-1 Destroys Tumor Vessels |
 |
|
 |
| |
 |
|
Tumor cells |
 |
|
Tumor releases signals inducing growth of blood vessels |
 |
|
Endothelial cells divide, blood vessels grows towards tumor |
 |
|
EndoTAG® attacks activated endothelial cells and destroys blood vessel.Thereby the blood supply of the tumor is
impaired |
|
Liposomal technology for drug development
MediGene’s drug candidate EndoTAG®-1 derived from MediGene’ s EndoTAG® technology.
EndoTAG®-1 is a novel composition of paclitaxel combined with neutral and cationic lipids. The drug candidate attaches itself selectively to newly developed, negatively
charged endothelial cells in tumor blood vessels, thus attacking only the blood supply of tumors and not that of healthy tissue. By doing this, EndoTAG®-1 prevents the
formation of new blood vessels in tumor tissue.
Compared to tumor cells, endothelial cells are genetically stable. MediGene assumes that due to this characteristic, EndoTAG®-1 can be used in the treatment of those
tumors that have already developed a resistance to conventional paclitaxel therapy.
MediGene has successfully provided proof of concept of EndoTAG®-1. A controlled phase II clinical trial for pancreatic cancer showed significantly increased survival
rates of those patients treated with EndoTAG®-1 and gemcitabine combination therapy. A phase II clinical trial in triple negative breast cancer also showed a positive
efficacy trend of EndoTAG®-1 combination therapy.
|
|
|
European and US authorities have granted orphan drug designation for EndoTAG®-1. This status affords
certain benefits in the development, approval, and, under certain circumstances, the commercialization of the drug.
European and US authorities have granted orphan drug designation for EndoTAG®-1. This status affords certain benefits in the development, approval, and, under certain
circumstances, the commercialization of the drug.
Outlook
MediGene continues to target signing one or more partnerships for the further development and future commercialization of EndoTAG®-1.
EndoTAG® is a trademark of MediGene AG
|
